Mohammed Dar

Mohammed joined Immunocore in April 2019 as Head of Clinical Development and Chief Medical Officer. Mohammed has over 15 years of pharmaceutical industry experience in the field of oncology.

Before joining Immunocore, Mohammed was Vice President, Clinical Development, Oncology, R&D at MedImmune and spent 10 years at GSK in roles of increasing responsibility focused on early clinical development in oncology. While at MedImmune, he led the clinical trials and teams supporting the approval of anti-PD-L1 checkpoint inhibitor, durvalumab, and anti-CD22 immunotoxin, moxetumomab. Mohammed received his Bachelor’s Degree in Chemistry from the University of North Carolina at Chapel Hill and his M.D. and Internal Medicine training from Duke University School of Medicine. He went on to complete his Fellowship in Hematology and Oncology at the National Cancer Institute.